Table 5 Frameshift CALR variant classification using the alpha helix propensity model (AGADIR score) in patients with non-type 1/2 mutant CALR variants. Subsequently new amino acids are shown in bold, common 3′ end are shown in italics.

From: CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms

No. of patient (n = 5)

CALR variant

AGADIR helix propensity score (T = 25 °C)

Nucleotide Change

Amino Acid Sequence

Amino Acid Change

1

Type 2-like

32.05

c.1127_1145del19

p.(Arg376Glnfs*48)

AAEKQMKDKQDEEQRLKEEEEDK KQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

2

Type 2-like

37.24

c.1154_1154delAinsGTTGTC

p.(Arg376Glnfs*48)

AAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDSCRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

3

Type 2-like

46.58

c.1154_1154delAinsTTTATC

p.(Lys385Ilefs*47)

AAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDIYRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

4

Type 2-like

31.05

c.1132_1153del22

p.(Glu378Argfs*45)

AAEKQMKDKQDEEQRLKEEEEDKKRKRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

5

Type 2-like

32.43

c.1114_1144del31

p.(Glu372Glnfs*48)

AAEKQMKDKQDEEQRLKEEEQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

 

Type 1

17.50

c.1092_1143del52

p.(Leu367Thrfs*46)

AAEKQMKDKQDEEQRTRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

 

Type 2

40.02

c.1154_1155insTTGTC

p.(Lys385Asnfs*47)

AAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDNCRRMMRTKMRMRRMRRTRRKMRRKMSPARPRTSCREACLQGWTEA

 

Wild-type

33.62

Wild-type

Wild-type

AAEKQMKDKQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL